UBS Initiates Coverage on Crinetics Pharmaceuticals, Inc. (CRNX) with Buy
Rating Change UBS analysts initiated coverage on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) with a Buy rating on July 02, 2026. Market Context Crinetics Pharmaceuticals, Inc.
Read more
